Sanofi, a global leader in healthcare - Sanofi · 2019-01-10 · Nanobodies are the next generation...

1

Transcript of Sanofi, a global leader in healthcare - Sanofi · 2019-01-10 · Nanobodies are the next generation...

Page 1: Sanofi, a global leader in healthcare - Sanofi · 2019-01-10 · Nanobodies are the next generation of antibody-derived biologics and have great potential. They are being developed

Properties of Nanobodies and their discovery via phage displaytheory.bio.uu.nl/immbio/sheets/Practica_intro.Nanobody_Platform.pdf · • Nanobodies combine advantages of antibodies

Properties of Nanobodies and their discovery via phage displaytheory.bio.uu.nl/immbio/sheets/Practica_intro.Nanobody_Platform.pdf · • Nanobodies combine advantages of antibodies

Case Study / Sanofi

Case Study / Sanofi

Nanobodies: Natural Single-Domain Antibodies

Nanobodies: Natural Single-Domain Antibodies

The Therapeutic Potential of Nanobodies · 2020-01-27 · Nanobodies: Therapeuti Potential 13 IgGantibody.Anothercomplicationofusingantibodies originatesfromtheirrelativelylargesize,withdimensions

The Therapeutic Potential of Nanobodies · 2020-01-27 · Nanobodies: Therapeuti Potential 13 IgGantibody.Anothercomplicationofusingantibodies originatesfromtheirrelativelylargesize,withdimensions

Annual Review 2013 - Protecting life, giving hope - sanofi.no 4 SANOFI – ANNUAL REVIEW 2013 SANOFI – ANNUAL REVIEW 2013 5 SANOFI RETURNS TO GROWTH 2 013 was pivotal for Sanofi,

Annual Review 2013 - Protecting life, giving hope - sanofi.no 4 SANOFI – ANNUAL REVIEW 2013 SANOFI – ANNUAL REVIEW 2013 5 SANOFI RETURNS TO GROWTH 2 013 was pivotal for Sanofi,

Synvisc PAP Application 2016 08 29 - pparx.org used by the Program sponsor, Sanofi US, its affiliated companies (i.e. Sanofi Pasteur U.S. and Genzyme, a Sanofi Company), The Sanofi

Synvisc PAP Application 2016 08 29 - pparx.org used by the Program sponsor, Sanofi US, its affiliated companies (i.e. Sanofi Pasteur U.S. and Genzyme, a Sanofi Company), The Sanofi

The CSR strategy at Sanofi: our materiality approachMatérialité RSE Sanofi – Matinée Comité 21 - 11 juin 2014 |1. 2 SANOFI AT A GLANCE Matérialité RSE Sanofi – Matinée Comité

The CSR strategy at Sanofi: our materiality approachMatérialité RSE Sanofi – Matinée Comité 21 - 11 juin 2014 |1. 2 SANOFI AT A GLANCE Matérialité RSE Sanofi – Matinée Comité

Sanofi Aventis

Sanofi Aventis

Nanobodies as Affinity Capture Reagents2019... · different nanobodies [Nb1, Nb1.1, Nb2, Nb3] B. Affinity capture experiment testing five different nanobodies [Nb 1, Nb1.1, Nb2, Nb3,

Nanobodies as Affinity Capture Reagents2019... · different nanobodies [Nb1, Nb1.1, Nb2, Nb3] B. Affinity capture experiment testing five different nanobodies [Nb 1, Nb1.1, Nb2, Nb3,

Nanobodies and their medical applications

Nanobodies and their medical applications

Milind Khamkar - Sanofi

Milind Khamkar - Sanofi

Investigation of interactions between nanobodies and their ...

Investigation of interactions between nanobodies and their ...

MALARIA - Sanofi

MALARIA - Sanofi

HER2-directed antibodies, affibodies and nanobodies as drug … · 2020. 11. 12. · REVIEW ARTICLE HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in

HER2-directed antibodies, affibodies and nanobodies as drug … · 2020. 11. 12. · REVIEW ARTICLE HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in

Exploiting sequence and stability information for ... · llama nanobodies. Dromedary and alpaca nanobodies were obtained from phage-display screenings, representing high-affinity

Exploiting sequence and stability information for ... · llama nanobodies. Dromedary and alpaca nanobodies were obtained from phage-display screenings, representing high-affinity

The C1 Technology Platform - Dyadic International, Inc · 2020-04-21 · Market size – $8.6 Billion by 2022 1. Sanofi, and others. New Biologics. mAbs, Bispecifics, Fc-Fusions.

The C1 Technology Platform - Dyadic International, Inc · 2020-04-21 · Market size – $8.6 Billion by 2022 1. Sanofi, and others. New Biologics. mAbs, Bispecifics, Fc-Fusions.

2015 HALF-YEAR MANAGEMENT REPORT · 2015 HALF-YEAR MANAGEMENT REPORT 27 August 2015 1. REPORT OF THE BOARD OF DIRECTORS ... and with Genzyme (a Sanofi Company) to investigate Nanobodies

2015 HALF-YEAR MANAGEMENT REPORT · 2015 HALF-YEAR MANAGEMENT REPORT 27 August 2015 1. REPORT OF THE BOARD OF DIRECTORS ... and with Genzyme (a Sanofi Company) to investigate Nanobodies

Nanobodies raised against monomeric ɑ-synuclein inhibit ...10.1186/s12915-017-0390... · 1 Supplementary Information Nanobodies raised against monomeric ɑ-synuclein inhibit fibril

Nanobodies raised against monomeric ɑ-synuclein inhibit ...10.1186/s12915-017-0390... · 1 Supplementary Information Nanobodies raised against monomeric ɑ-synuclein inhibit fibril

Life Sciences - thamesvalleyberkshire.co.uk Documents/Data/International/Life... · Bayer Plc (HQ) Lonza Biologics Plc KEELER Ltd ... (Novartis, Roche, Merek and Co, Sanofi, and AstraZeneca)

Life Sciences - thamesvalleyberkshire.co.uk Documents/Data/International/Life... · Bayer Plc (HQ) Lonza Biologics Plc KEELER Ltd ... (Novartis, Roche, Merek and Co, Sanofi, and AstraZeneca)

NANOBODIES: promising reagents in basic¨кола'2017... · 2018-09-09 · NANOBODIES: promising reagents in basic research and biomedicine Introduction Clonal relationship and cell

NANOBODIES: promising reagents in basic¨кола'2017... · 2018-09-09 · NANOBODIES: promising reagents in basic research and biomedicine Introduction Clonal relationship and cell